ASCO GU 2024 Press Releases

Viewing 1-8 of 8 articles

Photocure Partner Asieris Presented Clinical Trial and Real-World Data on Hexvix in China at ASCO GU 2024

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Combination of Cabozantinib and Atezolizumab Offers Hope for Patients with Type of Advanced Prostate Cancer with Poor Prognosis

Bayer Reveals Latest Prostate Cancer Data at 2024 ASCO GU Cancers Symposium

Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers

Global GU Meeting Will Highlight New Approaches to Detect and Treat Prostate, Kidney, Bladder Cancers

Two Asieris Studies in the Field of Bladder Cancer Selected for Oral and Poster Presentations at the 2024 American Society of Clinical Oncology Genitourinary Cancer Symposium, Potentially Offering New Disease Management Options for Patients